BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants to purchase Common Stock in lieu thereof (the “Pre-Funded Warrants”), and accompanying common warrants to purchase Common Stock (or Pre-Funded warrants in lieu thereof) (the “Common Warrants,” and together with the Common Stock and Pre-Funded Warrants, the “Securities”), excluding the proceeds, if any, from the exercise of the Pre-Funded Warrants and the Common Warrants and before deducting offering expenses..

加利福尼亚州伯灵格姆，2024年5月2日（环球通讯社）--Corvus Pharmaceuticals，Inc（Corvus or the Company）（Nasdaq:CRVS）（GLOBAL NEWSWIRE），一家临床阶段的生物制药公司，今天宣布，它已经与新的和现有的投资者签订了一项证券购买协议，通过出售其每股面值0.0001美元的普通股（以下简称“普通股”）和购买普通股的预付认股权证（以下简称“预付认股权证”）以及购买普通股（或预付认股权证（以下简称“预付认股权证”）的附带认股权证（以下简称“普通认股权证”）以及普通股权证（以下简称“普通权证”）来筹集大约3060万美元的总收益股票和预支认股权证（以下简称“证券”），不包括行使预支认股权证和普通认股权证产生的收益（如有），并且在扣除发行费用之前。。

The offering includes participation from health-care dedicated investors including Point72, Samlyn Capital, Armistice Capital, OrbiMed, Puissance Capital and Altamont Pharmaceutical Holdings, and other existing investors including Richard Miller, the Company’s chief executive officer.

此次发售包括Point72、Samlyn Capital、Armistice Capital、OrbiMed、Puissance Capital和Altamont Pharmaceutical Holdings等医疗保健专业投资者的参与，以及包括该公司首席执行官理查德·米勒（Richard Miller）在内的其他现有投资者的参与。

The purchase and sale will be completed via a registered direct offering of 13,512,699 shares of Common Stock and accompanying Common Warrants to purchase 13,078,509 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) at a combined offering price of $1.7312 per Share, and Pre-Funded Warrants to purchase 4,144,085 shares of Common Stock and accompanying Common Warrants to purchase 4,010,927 shares of Common Stock (or Pre-Funded Warrants in lieu thereof) at a combined offering price of $1.7311 per share underlying each Pre-Funded Warrant and Common Warrant, which equals the offering price per share of the Common Stock and Common Warrant less the $0.0001 exercise price per share of the Pre-Funded Warrants.

购买和出售将通过以下方式完成：登记直接发行13512699股普通股和随附普通认股权证，以每股1.7312美元的合并发行价格购买13078509股普通股（或替代其的预支认股权证），以每股1.7311美元的合并发行价格购买4144085股普通股和随附普通认股权证，以每股1.7311美元的合并发行价格购买4010927股普通股（或替代其的预支认股权证），等于普通股和普通认股权证每股的发行价减去预支认股权证每股0.0001美元的行权价。

The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock and are exercisable at any time after the date of issuance, subject to certain ownership limitations. The Common Warrants have an exercise price of $3.50 per share of Common Stock (or $3.4999 per Pre-Funded Warrant in lieu thereof) and are exercisable at any time after the date of issuance, subject to certain ownership limitations, and expire on June 30, 2025.  .

预先出资的认股权证的行权价格为每股普通股0.0001美元，可在发行日期后的任何时间行权，但须受某些所有权限制。普通认股权证的行权价格为每股普通股3.50美元（或每股预付认股权证的行权价格为3.4999美元），可在发行日期后的任何时间行权，但须受某些所有权限制，并于2025年6月30日到期。

All of the Securities are being offered by Corvus. The offering is expected to close on or about May 6, 2024, subject to the satisfaction of customary closing conditions. Since the offering of the Securities was made without an underwriter or a placement agent, the Company will not be paying any underwriting discounts or placement agent fees in connection with the offering..

所有证券均由Corvus提供。预计本次发行将于2024年5月6日左右结束，但须符合惯例的结束条件。由于证券的发行没有承销商或配售代理，因此公司不会支付与发行相关的任何承销折扣或配售代理费。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽购买要约，也不构成在根据任何州或司法管辖区的证券法律注册或资格之前，在任何州或司法管辖区出售这些证券是非法的。。

The Securities are being offered by Corvus Pharmaceuticals pursuant to a registration statement on Form S-3 (File No. 333-270921) previously filed and declared effective by the Securities and Exchange Commission (“SEC”). A final prospectus supplement and accompanying base prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov..

这些证券由Corvus Pharmaceuticals根据之前由证券交易委员会（“SEC”）提交并宣布生效的表格S-3（文件号333-270921）上的登记声明提供。与拟议发行条款相关并描述其内容的最终补充招股说明书和随附基本招股说明书将提交给SEC，并可在SEC网站www.SEC.gov上查阅。。

About Corvus Pharmaceuticals

关于Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK.

Corvus Pharmaceuticals是一家临床阶段的生物制药公司，开创了ITK抑制的发展，作为一种针对多种癌症和免疫疾病的免疫治疗新方法。该公司的主要候选产品是索喹替尼，一种选择性抑制ITK的研究性口服小分子药物。

Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com..

它的其他临床阶段候选者正在开发用于各种癌症适应症。有关更多信息，请访问www.corvuspharma.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management and include, but are not limited to, statements regarding the timing for closing of the offering and the Company’s ability to complete the offering.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款含义内的前瞻性声明。这些前瞻性声明反映了管理层当前的信念和期望，包括但不限于关于发售结束时间和公司完成发售能力的声明。

In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance.

此外，当或如果在本新闻稿中使用“可能”、“可能”、“应该”、“预期”、“相信”、“估计”、“预期”、“打算”、“计划”、“预测”等词语以及与公司相关的类似表达及其变体，可能会识别出前瞻性陈述。前瞻性陈述既不是历史事实，也不是未来表现的保证。

Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the offering, the uncertainties inherent in the drug development process, including the Company’s programs’ clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the s.

虽然公司认为这些前瞻性声明中反映的期望是合理的，但公司不能保证这些期望会被证明是正确的。读者应注意，由于各种因素，实际结果、活动水平、安全性、性能或事件和情况可能与公司前瞻性声明中明示或暗示的结果、活动水平、安全性、性能或事件和情况存在重大差异，包括与市场条件相关的风险和不确定性，以及与发售相关的交割条件的满意度，药物开发过程中固有的不确定性，包括公司计划的临床开发阶段，设计和进行临床前和临床试验的过程，监管审批流程，监管备案的时间，与制造药品相关的挑战，公司成功建立，保护和捍卫其知识产权的能力以及其他可能影响s的事项。

INVESTOR CONTACT:

投资者联系人：

Leiv Lea

完整路径

Chief Financial Officer

首席财务官

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals，股份有限公司。

+1-650-900-4522

+1-650-900-4522

llea@corvuspharma.com

llea@corvuspharma.com

MEDIA CONTACT:

媒体联系人：

Sheryl Seapy

谢丽尔·西皮。

Real Chemistry

真正的化学

+1-949-903-4750

+1-949-903-4750

sseapy@realchemistry.com

sseapy@realchemistry.com